Systemic Lupus Erythematosus Treatment Guidelines

Foundation of SLE Treatment

The American College of Rheumatology recommends hydroxychloroquine as the cornerstone of SLE treatment for all patients, at doses not exceeding 5 mg/kg real body weight, with regular ophthalmological monitoring 1, 2
Glucocorticoids should be used at the lowest effective dose, with a target of less than 7.5 mg/day prednisone equivalent for maintenance, and rapid tapering and eventual withdrawal when possible 1, 2
Conventional immunosuppressants, such as azathioprine, mycophenolate mofetil, and methotrexate, continue to play important roles in organ-threatening disease and as steroid-sparing agents 3

Belimumab, a B-lymphocyte stimulator inhibitor, is recommended for patients with persistently active or flaring disease despite standard therapy, with a dosing option of 200 mg weekly for adults with SLE 2
The European League Against Rheumatism recommends considering belimumab for patients with high disease activity and inadequate response to standard therapy 2

Calcineurin inhibitors, especially tacrolimus, have emerged as effective treatment options for SLE, particularly for patients with nephrotic-range proteinuria and adverse prognostic factors 1, 3
Multitarget therapy combining mycophenolate mofetil with calcineurin inhibitors shows promise for patients with lupus nephritis 1, 3

For mild to moderate SLE without major organ involvement, hydroxychloroquine is recommended as baseline therapy, with low-dose glucocorticoids and methotrexate considered for symptom control and predominant articular and cutaneous manifestations 1, 2, 4
For moderate to severe SLE with major organ involvement, initial treatment with mycophenolate mofetil or low-dose intravenous cyclophosphamide combined with glucocorticoids is recommended, with consideration of MMF/CNI combination for nephrotic-range proteinuria 1, 3

The goal of treatment is to achieve complete response, defined as proteinuria less than 0.5-0.7 g/24 hours with normal GFR, by 12 months for lupus nephritis 3
Disease activity should be monitored using validated indices, such as BILAG, ECLAM, or SLEDAI, with regular assessment of clinical manifestations, laboratory tests, and immunological markers 2, 5

Patients with SLE should be assessed and managed for risk factors for atherosclerosis, hypertension, dyslipidemia, and diabetes, with consideration of low-dose aspirin for primary prevention of thrombosis in patients with antiphospholipid antibodies 2, 5
Estrogen-containing medications should be avoided due to increased thrombosis risk, and patients should be monitored for and prevented from developing osteoporosis, avascular necrosis, and infections 2, 5